SCM
CRBP icon

Superstring Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Superstring Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-57,644
Closed -$729K – 47
2025
Q3 		$729K Buy
+57,644
New +$548K 0.72% 32
2024
Q4 		– Sell
-25,401
Closed -$524K – 43
2024
Q3 		$524K Sell
25,401
-31,067
-55% -$1.59M 0.46% 24
2024
Q2 		$2.56M Buy
+56,468
New +$2.38M 3.22% 11

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Superstring Capital Management's CRBP Position: Q4 2025 in Review

Superstring Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2025, closing a stake of 57,644 shares — an estimated $729K sold.

Superstring Capital Management first reported a position in CRBP in Q2 2024 and held it in 3 quarters. The position peaked at $2.56M in Q2 2024. 100 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

  • Superstring Capital Management reported no remaining Corbus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Superstring Capital Management sold 57,644 Corbus Pharmaceuticals shares in Q4 2025, an estimated $729K.
  • Superstring Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Superstring Capital Management's Corbus Pharmaceuticals position peaked at $2.56M in Q2 2024.
  • 100 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.